Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Incorporated    LGND

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
134.89(c) 142.62(c) 156.01(c) 156.86(c) 162.94(c) Last
301 943 473 537 1 868 443 1 143 978 5 557 338 Volume
-0.12% +5.73% +9.39% +0.54% +3.88% Change
More quotes
Financials (USD)
Sales 2020 170 M - -
Net income 2020 -2,46 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1 304x
Yield 2020 -
Sales 2021 289 M - -
Net income 2021 65,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 40,4x
Yield 2021 -
Capitalization 2 620 M 2 620 M -
Capi. / Sales 2020 15,4x
Capi. / Sales 2021 9,07x
Nbr of Employees 115
Free-Float 95,8%
More Financials
Company
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science,... 
More about the company
Notations Surperformance© of Ligand Pharmaceuticals Incorporated
Trading Rating : Investor Rating :
More Ratings
All news about LIGAND PHARMACEUTICALS INCORPORATED
01/27INSIDER TRENDS : Insider at Ligand Pharmaceuticals Awarded Shares Portion of Whi..
MT
01/27INSIDER TRENDS : Ligand Pharmaceuticals Insider Exercises Options Extending 90-D..
MT
01/27INSIDER TRENDS : Ligand Pharmaceuticals Insider Awarded Shares Uses Portion to P..
MT
01/27INSIDER TRENDS : Insider at Ligand Pharmaceuticals Receives Stock Award Uses Por..
MT
01/21LIGAND PHARMACEUTICALS INCORPORATED : Fourth Quarter Financial Results to be Rep..
AQ
01/20LIGAND PHARMACEUTICALS INCORPORATED : Fourth Quarter Financial Results to be Rep..
BU
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
01/13LIGAND PHARMACEUTICALS INCORPORATED : Receives Milestone Payment from Merck
BU
2020LIGAND PHARMACEUTICALS INCORPORATED : and GSK Enter Global Collaboration and Lic..
AQ
2020LIGAND PHARMACEUTICALS INCORPORATED : and GSK Sign License Agreement to Target N..
MT
2020LIGAND PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
AQ
2020LIGAND PHARMACEUTICALS INCORPORATED : and GSK Enter Global Collaboration and Lic..
BU
2020LIGAND PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submissi..
AQ
2020LIGAND PHARMACEUTICALS INCORPORATED : INC Financial Statements and Exhibits (for..
AQ
2020INSIDER TRENDS : Ligand Pharmaceuticals Insider Exercises Option/Derivative Secu..
MT
More news
News in other languages on LIGAND PHARMACEUTICALS INCORPORATED
2020CAC40 : les 'flux' contrebalancent un sell off initial de -3%
2020CAC40 : tente de s'accrocher aux 4800 grâce au rebond WStreet
2020CAC40 : chute de -3% à l'ouverture mais le creux est 'payé'
2020CAC40 : décroche avant de nouvelles statistiques
2014LIGAND PHARMACEUTICALS INC. : publication des résultats trimestriels
More news
Chart LIGAND PHARMACEUTICALS INCORPORATED
Duration : Period :
Ligand Pharmaceuticals Incorporated Technical Analysis Chart | LGND | US53220K5048 | MarketScreener
Technical analysis trends LIGAND PHARMACEUTICALS INCORPORATED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 185,83 $
Last Close Price 162,94 $
Spread / Highest target 40,5%
Spread / Average Target 14,1%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
NameTitle
John L. Higgins Chief Executive Officer & Director
Matthew William Foehr President & Chief Operating Officer
John W. Kozarich Chairman
Matthew Edward Korenberg Chief Financial Officer & Executive VP-Finance
Eric Vajda Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
LIGAND PHARMACEUTICALS INCORPORATED63.84%2 620
MODERNA, INC.49.07%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.-3.44%34 576
SEAGEN INC.-7.11%31 230